{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T19:07:18Z","timestamp":1761419238732,"version":"3.37.3"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP15ck0106076","JP17ck0106354"],"award-info":[{"award-number":["JP15ck0106076","JP17ck0106354"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Fund","award":["26-A-4, 29-A-3"],"award-info":[{"award-number":["26-A-4, 29-A-3"]}]}],"content-domain":{"domain":["pancreatology.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.pan.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T12:58:05Z","timestamp":1532696285000},"page":"841-845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407)"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8123-5298","authenticated-orcid":false,"given":"Junki","family":"Mizusawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fukutomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Ioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2018.07.007_bib1","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase iii study of gemcitabine plus s-1, s-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and taiwan: gest study","volume":"31","author":"Ueno","year":"2013","journal-title":"J\u00a0Clin Oncol: Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.pan.2018.07.007_bib2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jjco\/hyq011","article-title":"Phase ii study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: jcog0506","volume":"40","author":"Ishii","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.pan.2018.07.007_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jjco\/hys177","article-title":"The hepatobiliary and pancreatic oncology (hbpo) group of the Japan clinical oncology group (jcog): History and future direction","volume":"43","author":"Furuse","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.pan.2018.07.007_bib4","first-page":"621PD","article-title":"Randomized phase ii study of s-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (lapc): final analysis of jcog 1106","author":"Ioka","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2018.07.007_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Folfirinox versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2018.07.007_bib6","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/cas.12501","article-title":"Phase ii study of folfirinox for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"105","author":"Okusaka","year":"2014","journal-title":"Canc Sci"},{"key":"10.1016\/j.pan.2018.07.007_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.4111","article-title":"Phase ii study of modified folfirinox for chemotherapy-na\u00efve patients with metastatic pancreatic cancer","volume":"34","author":"Ueno","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2018.07.007_bib8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2018.07.007_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","article-title":"Phase i\/ii study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"77","author":"Ueno","year":"2016","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.pan.2018.07.007_bib10","first-page":"279","article-title":"Ca 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer","volume":"44","author":"Ishii","year":"1997","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.pan.2018.07.007_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc"},{"key":"10.1016\/j.pan.2018.07.007_bib12","unstructured":"Common terminology criteria for adverse events v4.0 (ctcae) https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_4.03.xlsx."},{"key":"10.1016\/j.pan.2018.07.007_bib13","first-page":"1375","article-title":"Randomized phase ii clinical trials","volume":"69","author":"Simon","year":"1985","journal-title":"Canc Treat Rep"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390318306343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390318306343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T09:31:33Z","timestamp":1538040693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390318306343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1424390318306343"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2018.07.007","relation":{},"ISSN":["1424-3903"],"issn-type":[{"type":"print","value":"1424-3903"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407)","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}